Chemotherapies can augment tumor immunity, mostly by inducing immunogenic cell death, debulking the tumor mass, and depleting inhibitory immune cell populations.21 Based on the poor RR to monotherapy PD-1 blockade in our cohort, we suggest further investigation of chemo-immunotherapy in the setting of MU-SCC. The gene discussed is PDCD1; the disease is neoplasm.